Fulvestrant or capecitabine after chemo for metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and your breast cancer cannot be cured with surgery or radiation.
- Your tumor is estrogen and/or progesterone “receptor positive” (ER and/or PR positive) and HER2 negative.
- After 4 to 8 courses of first-line chemotherapy, your cancer did not worsen (complete response, partial response, or stable disease).
- You are not currently pregnant or breastfeeding.
- Your body function tests are good enough for treatment (blood counts, liver, and kidney function) and side effects from prior treatment are mostly improved (to grade 1 or less).
- You can do study-required scans within 3 weeks before starting maintenance treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adjusting the dose of the oral chemotherapy capecitabine over time can control metastatic breast cancer that is estrogen-receptor positive (ER+) and HER2−. It is designed for patients who are starting capecitabine or have just started it, and the study will monitor blood changes and tumor response closely.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This trial tests a combination of three drugs (lenvatinib, pembrolizumab, and fulvestrant) for people with a certain type of advanced breast cancer that has stopped responding to previous hormone therapy. The goal is to see if this new combination can help shrink or control the cancer.
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests a combination of two drugs—entinostat and fulvestrant—for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has stopped responding to standard hormone therapy and a CDK4/6 inhibitor. The goal is to see if this combo can help shrink tumors or slow their growth.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.